Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Certolizumab pegol concentrations are associated with endoscopic outcomes in Crohn's

A study in the latest issue of the Clinical Gastroenterology & Hepatology evaluates the association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

News image

Monitoring plasma concentrations of anti–tumor necrosis factor agents could optimize treatment of patients with Crohn's disease.

In a post hoc analysis of data from a clinical trial, Dr Jean–Frédéric Colombel and colleagues compared the relationship between plasma concentrations of certolizumab pegol and endoscopic and clinical responses and remission with certolizumab pegol therapy in patients with moderate to severe ileocolonic Crohn's disease.

The research team analyzed data from the Endoscopic Mucosal Improvement in Patients with Active Crohn's Disease Treated with certolizumab pegol trial, from 89 adult patients with active endoscopic Crohn's disease.

Patients received subcutaneous certolizumab pegol (400 mg) at weeks 0, 2, and 4 and then every 4 weeks until week 52.

Higher concentrations of certolizumab pegol at week 8 were associated with endoscopic response
Clinical Gastroenterology & Hepatology

Endoscopic evaluations were performed at weeks 0, 10, and 54.

The research team found that blood samples were collected to measure certolizumab pegol plasma concentrations at weeks 8 and 54.

Certolizumab pegol quartiles at weeks 8 and 54 were correlated with endoscopic response and remission at weeks 10 and 54, respectively.

The team noted that higher concentrations of certolizumab pegol at week 8 were associated with endoscopic response, and remission at week 10.

At week 54, the research team found that rates of endoscopic remission correlated with plasma concentrations of certolizumab pegol.

There was a significant inverse relationship between plasma concentrations of certolizumab pegol, and baseline levels of C-reactive protein and body weight.

Dr Colombel's team concludes, "Endoscopic response and remission are associated with higher plasma concentrations of certolizumab pegol in patients with moderate to severe ileocolonic Crohn's disease."

"These results support the need to consider the pharmacokinetics of anti–tumor necrosis factor agents and therapeutic drug monitoring to optimize treatment."

Clin Gastroenterol Hepatol 2014: 12(3): 423-431.e1
26 February 2014

Go to top of page Email this page Email this page to a colleague

 01 September 2014

Advanced search
 01 September 2014 
Fecal hemoglobin and colorectal cancer screening
 01 September 2014 
Genetic variants in alcoholic liver disease
 01 September 2014 
Risks with anti-TNF in pediatric IBD
 29 August 2014 
NSAID-induced small intestinal injury and diaphragm disease
 29 August 2014 
Symptom evaluation in functional dyspepsia
 29 August 2014 
Gluten-free diet for asymptomatic celiac disease
 28 August 2014 
Predictoris of C. diff in out-patients
 28 August 2014 
Detection of gastroesophageal reflux symptoms
 28 August 2014 
Colorectal-cancer mortality after adenoma removal
 27 August 2014 
Endoscopy outcomes in community hospital vs tertiary academic centers
 27 August 2014 
UV exposure and IBD hospitalizations
 27 August 2014 
Hepatocellular carcinoma screening in liver disease
 26 August 2014 
NAFLD and gastroesophageal reflux symptoms
 26 August 2014 
Adalimumab-treated patients with ulcerative colitis
 26 August 2014 
Wound healing after abdominoperineal resection
 25 August 2014 
Surgical management of rectourethral fistulas
 25 August 2014 
Biomarker analysis in biopsies for ulcerative colitis
 25 August 2014 
Ileocolic resection in Crohn's disease
 22 August 2014 
Outlier identification in colorectal surgery
 22 August 2014 
Endoscopic submucosal dissection for squamous esophageal cancer
 22 August 2014 
Adherence to Rome criteria in functional dyspepsia trials
 21 August 2014 
Screening for Barrett’s esophagus
 21 August 2014 
Colorectal cancer mortality in Brazil
 21 August 2014 
Eosinophilic esophagitis
 20 August 2014 
Rectal surgery mortality
 20 August 2014 
Chemotherapy-induced gastrointestinal mucositis
 20 August 2014 
Stool methylated DNA markers and colorectal cancer resection
 19 August 2014 
Recurrent C. difficile infection in out-patients
 19 August 2014 
Racial disparities and colon cancer
 19 August 2014 
Variability of colonoscopy preparation instructions
 18 August 2014 
The evolution of urban C. difficile
 18 August 2014 
Metabolomic analysis in IBD
 18 August 2014 
Enhanced T-cell response in acute-on-chronic Hep B
 15 August 2014 
Abdominal pain in IBS
 15 August 2014 
Gene expression biomarker in ulcerative colitis
 15 August 2014 
Population-based fecal immunochemical test screening
 14 August 2014 
Transnasal vs transoral endoscopy
 14 August 2014 
Radiation exposure in gastroenterology
 14 August 2014 
Dietary fibre and diverticular disease
 13 August 2014 
Fecal immunochemical test screening
 13 August 2014 
Adherence to Rome criteria in functional dyspepsia
 13 August 2014 
Flexible sigmoidoscopy screening
 12 August 2014 
Eosinophilic esophagitis and celiac disease
 12 August 2014 
Management of Lynch syndrome
 12 August 2014 
Risk of cancer under immunosuppressive therapy in IBD
 11 August 2014 
Gut microbiota in chemotherapy-induced GI mucositis
 11 August 2014 
Risk of GI bleeds with anticoagulants
 11 August 2014 
Social media in health-care
 08 August 2014 
Endoscopy nurse-administered propofol sedation performance
 08 August 2014 
Therapy for biliary tract cancer
 08 August 2014 
Surgeon volume and esophagectomy survival
 07 August 2014 
Global consensus on perianal fistulizing Crohn's disease
 07 August 2014 
Smoking cessation and age of onset of ulcerative colitis
 07 August 2014 
Colonoscopy length and training duration
 06 August 2014 
Hepatitis C virus infection in the United States
 06 August 2014 
Pediatric to adult IBD care
 06 August 2014 
Biomarker of disease activity in IBD
 05 August 2014 
Rising incidence of celiac disease
 05 August 2014 
Socioeconomic status and IBS
 05 August 2014 
Bowel dysfunction after sphincter-preserving rectal cancer surgery

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us